Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 19;7:169. doi: 10.1038/s41541-022-00580-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — BALB/c and K18-hACE2-Tg mice were immunized with WT-S, BA1-S, WT-S prime and BA1-S boost, WT-S and BA1-S cocktail, or PBS control in the presence of adjuvants 3 times at a 3-week interval. Sera were collected 10 days after the second immunization and 10, 30, and 90 days, respectively, after the third immunization for the detection of neutralizing antibodies against pseudotyped viruses encoding the S protein of the original SARS-CoV-2 strain and Omicron subvariants. NT₅₀ was expressed as 50% neutralizing antibody titers against pseudovirus infection in 293T cells expressing the hACE2 receptor (hACE2/293T). NT₅₀ against pseudotyped SARS-CoV-2 original wild-type strain (a, f), BA1 (b, g), BA2 (c, h), BA2.12.1 (d, i), and BA5 (e, j) 10 days after the third immunization in BALB/c (a–e) and K18-hACE2-Tg (f–j) mice, respectively. NT₅₀ against the afore-mentioned pseudotyped SARS-CoV-2 original wild-type strain (k), BA1 (l), BA2 (m), BA2.12.1 (n), and BA5 (o) 10 days after the second immunization, as well as 10, 30, and 90 days, respectively, after the third immunization. The data are expressed as mean ± s.e.m. of quadruple wells from pooled sera of five mice in each group. Statistical significance among different vaccination groups was analyzed using Ordinary one-way ANOVA, and * (P < 0.05), ** (P < 0.01), and *** (P < 0.001) indicate significant differences. The experiments were repeated twice, leading to similar results.